Multi-faceted Evaluations Following Weight Reduction in Subjects With Metabolic Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Central obesity, core of metabolic syndrome, has been recognized as one of the rooting factors for development of diabetes and cardiovascular disease. Although efforts have been devoted to the studies of central obesity and/or metabolic syndrome, much remained unknown as to how obesity influences cellular as well as cardiac functions, what is the central regulation of one's body weight.
Weight loss is an undisputed way to improve cardiovascular and metabolic disorders in obese individuals. Previous studies have demonstrated that weight loss by 5% of initial weight universally provide substantial benefits in these subjects. However, there are little integrated research teams, composed of different disciplines, share common weight reduction program to look at different aspects of weight reduction in non-diabetic individuals with metabolic syndrome. The significances of this proposal we plan to target, namely Rho kinase activity from peripheral leukocyte, several cardiac functions measured by noninvasive technique (VP-2000) and MRI, circulating brain-derived neurotrophic factors (BDNF) levels, are fully explained detailed in each sub-proposal.
In order to accomplish this integrated proposal, we will form research teams including endocrinologists, cardiologists, radiologists, and a coordinating data center. We pan to recruit 40 non-diabetic individuals with metabolic syndrome to participate this 12-16 weeks weight reduction program. Twenty-five age, sex matched non-diabetes lean will be served as controls. Oral glucose tolerance test, fasting blood obtained, noninvasive vascular and MRI examinations will be applied before and after weight reduction program in those achieving at least 5% loss of initial weight.
In summary, this study will investigate the effects of weight loss on (1) Rho kinase activity obtained from peripheral leukocyte; (2). Aortic stiffness, central aortic pressure and hemodynamic by a noninvasive vascular profiling system (VP-2000); (3) Brain function specifically reflecting by circulating BDNF; (4). Aortic elastic properties and left ventricular function by using MRI examinations, in non-diabetic individuals of metabolic syndrome.
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome |
Behavioral: Lifestyle Counseling |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of Wight Reduction by Life-style Modification |
- change of body weight [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
- Change of Rho kinase [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
- Change of central aortic blood pressure and related hemodynamics [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
- Change of Brain-derived neurotrophic factor [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
- Change of MRI images of cardiac function [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
- Change of profiles before and after OGTT [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 40 |
| Study Start Date: | April 2008 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Life-style modification
Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
|
Behavioral: Lifestyle Counseling
Diet control with exercise
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 20 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age between 20 and 65 years
- Metabolic syndrome by IDF 2005 criteria
Exclusion Criteria:
- known diabetes
- obesity due to endocrinologic disorders
- Psychological disorder or using psychological medications
- Abnormal liver function (three-fold upper normal limit)
- Abnormal renal function (1.5-fold upper normal limit)
- Investigator judgement for abnormal clinical data
- Life-threatening disease
- Acute infective status
- Alcohol or drug abuse
- pregnant potency without prevention
- receiving other clinical trial in recently three months
Contacts and Locations| Taiwan | |
| Taichung Veterans General Hospital | |
| Taichung, Taiwan, 407 | |
| Principal Investigator: | Wayne HH Sheu, MD, PhD | Taichung Veterans General Hospital |
More Information
No publications provided by Taichung Veterans General Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Wayne Huey-Herng Sheu, Taichung Veterans General Hospital |
| ClinicalTrials.gov Identifier: | NCT01065753 History of Changes |
| Other Study ID Numbers: | C07220 |
| Study First Received: | February 8, 2010 |
| Last Updated: | February 8, 2010 |
| Health Authority: | Taiwan: Institutional Review Board |
Keywords provided by Taichung Veterans General Hospital:
|
Rho kinase Brain-derived neurotrophic factor |
Additional relevant MeSH terms:
|
Metabolic Syndrome X Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013